共 19 条
[1]
Conn J.W., The evolution of primary aldosteronism, Harvey Lect 1954-1967, 62, pp. 257-291, (1968)
[2]
Ferriss J.B., Beevers D.G., Boddy K., Et al., The treatment of low-renin (“primary”) hyperaldosteronism, Am Heart J, 96, pp. 97-109, (1978)
[3]
Manger W.M., Gifford R.W., Pheochromocytoma, (1977)
[4]
Stanley J.C., Fry W.J., Surgical treatment of renovascular hypertension, Arch Surg, 112, pp. 1291-1297, (1977)
[5]
Kaufman J.J., Renovascular hypertension: the UCLA experience, J Urol, 121, pp. 139-144, (1979)
[6]
Streeten D.H.P., Anderson G.H., Hypertension: relating drug therapy to pathogenetic mechanisms, Progress in Drug Research, pp. 176-194, (1988)
[7]
Vaughan E.d., Buhler F.R., Laragh J.H., Et al., Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability, Am J Med, 55, pp. 402-414, (1973)
[8]
Streeten D.H.P., Anderson G.H., Freiberg J.M., Dalakos T.G., Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension, New Engl J Med, 292, pp. 657-662, (1975)
[9]
Streeten D.H.P., Anderson G.H., Outpatient experience with saralasin Kidney Int, 15, pp. S44-S52, (1979)
[10]
Streeten D.H.P., Anderson G.H., Howland T., Et al., Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension, Hypertension, 11, pp. 78-83, (1988)